Hydroxyprogesterones: Metabolites or derivatives of PROGESTERONE with hydroxyl group substitution at various sites.Progestins: Compounds that interact with PROGESTERONE RECEPTORS in target tissues to bring about the effects similar to those of PROGESTERONE. Primary actions of progestins, including natural and synthetic steroids, are on the UTERUS and the MAMMARY GLAND in preparation for and in maintenance of PREGNANCY.17-alpha-Hydroxyprogesterone: A metabolite of PROGESTERONE with a hydroxyl group at the 17-alpha position. It serves as an intermediate in the biosynthesis of HYDROCORTISONE and GONADAL STEROID HORMONES.Adrenal Hyperplasia, Congenital: A group of inherited disorders of the ADRENAL GLANDS, caused by enzyme defects in the synthesis of cortisol (HYDROCORTISONE) and/or ALDOSTERONE leading to accumulation of precursors for ANDROGENS. Depending on the hormone imbalance, congenital adrenal hyperplasia can be classified as salt-wasting, hypertensive, virilizing, or feminizing. Defects in STEROID 21-HYDROXYLASE; STEROID 11-BETA-HYDROXYLASE; STEROID 17-ALPHA-HYDROXYLASE; 3-beta-hydroxysteroid dehydrogenase (3-HYDROXYSTEROID DEHYDROGENASES); TESTOSTERONE 5-ALPHA-REDUCTASE; or steroidogenic acute regulatory protein; among others, underlie these disorders.17-alpha-Hydroxypregnenolone: A 21-carbon steroid that is converted from PREGNENOLONE by STEROID 17-ALPHA-HYDROXYLASE. It is an intermediate in the delta-5 pathway of biosynthesis of GONADAL STEROID HORMONES and the adrenal CORTICOSTEROIDS.Steroid 21-Hydroxylase: An adrenal microsomal cytochrome P450 enzyme that catalyzes the 21-hydroxylation of steroids in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP21 gene, converts progesterones to precursors of adrenal steroid hormones (CORTICOSTERONE; HYDROCORTISONE). Defects in CYP21 cause congenital adrenal hyperplasia (ADRENAL HYPERPLASIA, CONGENITAL).Cortodoxone: 17,21-Dihydroxypregn-4-ene-3,20-dione. A 17-hydroxycorticosteroid with glucocorticoid and anti-inflammatory activities.Androstenedione: A delta-4 C19 steroid that is produced not only in the TESTIS, but also in the OVARY and the ADRENAL CORTEX. Depending on the tissue type, androstenedione can serve as a precursor to TESTOSTERONE as well as ESTRONE and ESTRADIOL.Pregnanetriol: A metabolite of 17-ALPHA-HYDROXYPROGESTERONE, normally produced in small quantities by the GONADS and the ADRENAL GLANDS, found in URINE. An elevated urinary pregnanetriol is associated with CONGENITAL ADRENAL HYPERPLASIA with a deficiency of STEROID 21-HYDROXYLASE.Pregnanes: Saturated derivatives of the steroid pregnane. The 5-beta series includes PROGESTERONE and related hormones; the 5-alpha series includes forms generally excreted in the urine.Pregnancy, Twin: The condition of carrying TWINS simultaneously.Dehydroepiandrosterone: A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion.Hyperandrogenism: A condition caused by the excessive secretion of ANDROGENS from the ADRENAL CORTEX; the OVARIES; or the TESTES. The clinical significance in males is negligible. In women, the common manifestations are HIRSUTISM and VIRILISM as seen in patients with POLYCYSTIC OVARY SYNDROME and ADRENOCORTICAL HYPERFUNCTION.17-Ketosteroids: Steroids that contain a ketone group at position 17.Fluoxymesterone: An anabolic steroid that has been used in the treatment of male HYPOGONADISM, delayed puberty in males, and in the treatment of breast neoplasms in women.Adrenocortical Hyperfunction: Excess production of ADRENAL CORTEX HORMONES such as ALDOSTERONE; HYDROCORTISONE; DEHYDROEPIANDROSTERONE; and/or ANDROSTENEDIONE. Hyperadrenal syndromes include CUSHING SYNDROME; HYPERALDOSTERONISM; and VIRILISM.Hirsutism: A condition observed in WOMEN and CHILDREN when there is excess coarse body hair of an adult male distribution pattern, such as facial and chest areas. It is the result of elevated ANDROGENS from the OVARIES, the ADRENAL GLANDS, or exogenous sources. The concept does not include HYPERTRICHOSIS, which is an androgen-independent excessive hair growth.Nafarelin: A potent synthetic agonist of GONADOTROPIN-RELEASING HORMONE with 3-(2-naphthyl)-D-alanine substitution at residue 6. Nafarelin has been used in the treatments of central PRECOCIOUS PUBERTY and ENDOMETRIOSIS.Clitoris: An erectile structure homologous with the penis, situated beneath the anterior labial commissure, partially hidden between the anterior ends of the labia minora.Hydrocortisone: The main glucocorticoid secreted by the ADRENAL CORTEX. Its synthetic counterpart is used, either as an injection or topically, in the treatment of inflammation, allergy, collagen diseases, asthma, adrenocortical deficiency, shock, and some neoplastic conditions.Adrenocorticotropic Hormone: An anterior pituitary hormone that stimulates the ADRENAL CORTEX and its production of CORTICOSTEROIDS. ACTH is a 39-amino acid polypeptide of which the N-terminal 24-amino acid segment is identical in all species and contains the adrenocorticotrophic activity. Upon further tissue-specific processing, ACTH can yield ALPHA-MSH and corticotrophin-like intermediate lobe peptide (CLIP).Pregnancy, Triplet: The condition of carrying TRIPLETS simultaneously.Steroid 17-alpha-Hydroxylase: A microsomal cytochrome P450 enzyme that catalyzes the 17-alpha-hydroxylation of progesterone or pregnenolone and subsequent cleavage of the residual two carbons at C17 in the presence of molecular oxygen and NADPH-FERRIHEMOPROTEIN REDUCTASE. This enzyme, encoded by CYP17 gene, generates precursors for glucocorticoid, androgen, and estrogen synthesis. Defects in CYP17 gene cause congenital adrenal hyperplasia (ADRENAL HYPERPLASIA, CONGENITAL) and abnormal sexual differentiation.Testosterone: A potent androgenic steroid and major product secreted by the LEYDIG CELLS of the TESTIS. Its production is stimulated by LUTEINIZING HORMONE from the PITUITARY GLAND. In turn, testosterone exerts feedback control of the pituitary LH and FSH secretion. Depending on the tissues, testosterone can be further converted to DIHYDROTESTOSTERONE or ESTRADIOL.Pregnenolone: A 21-carbon steroid, derived from CHOLESTEROL and found in steroid hormone-producing tissues. Pregnenolone is the precursor to GONADAL STEROID HORMONES and the adrenal CORTICOSTEROIDS.Polycystic Ovary Syndrome: A complex disorder characterized by infertility, HIRSUTISM; OBESITY; and various menstrual disturbances such as OLIGOMENORRHEA; AMENORRHEA; ANOVULATION. Polycystic ovary syndrome is usually associated with bilateral enlarged ovaries studded with atretic follicles, not with cysts. The term, polycystic ovary, is misleading.Dehydroepiandrosterone Sulfate: The circulating form of a major C19 steroid produced primarily by the ADRENAL CORTEX. DHEA sulfate serves as a precursor for TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE.Androgens: Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power.Progesterone: The major progestational steroid that is secreted primarily by the CORPUS LUTEUM and the PLACENTA. Progesterone acts on the UTERUS, the MAMMARY GLANDS and the BRAIN. It is required in EMBRYO IMPLANTATION; PREGNANCY maintenance, and the development of mammary tissue for MILK production. Progesterone, converted from PREGNENOLONE, also serves as an intermediate in the biosynthesis of GONADAL STEROID HORMONES and adrenal CORTICOSTEROIDS.Cosyntropin: A synthetic peptide that is identical to the 24-amino acid segment at the N-terminal of ADRENOCORTICOTROPIC HORMONE. ACTH (1-24), a segment similar in all species, contains the biological activity that stimulates production of CORTICOSTEROIDS in the ADRENAL CORTEX.Adrenal Glands: A pair of glands located at the cranial pole of each of the two KIDNEYS. Each adrenal gland is composed of two distinct endocrine tissues with separate embryonic origins, the ADRENAL CORTEX producing STEROIDS and the ADRENAL MEDULLA producing NEUROTRANSMITTERS.Puberty, Precocious: Development of SEXUAL MATURATION in boys and girls at a chronological age that is 2.5 standard deviations below the mean age at onset of PUBERTY in the population. This early maturation of the hypothalamic-pituitary-gonadal axis results in sexual precocity, elevated serum levels of GONADOTROPINS and GONADAL STEROID HORMONES such as ESTRADIOL and TESTOSTERONE.Dictionaries, MedicalDictionaries as Topic: Lists of words, usually in alphabetical order, giving information about form, pronunciation, etymology, grammar, and meaning.Injections, Intramuscular: Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it.Patents as Topic: Exclusive legal rights or privileges applied to inventions, plants, etc.Inventions: A novel composition, device, or process, independently conceived de novo or derived from a pre-existing model.Intellectual Property: Property, such as patents, trademarks, and copyright, that results from creative effort. The Patent and Copyright Clause (Art. 1, Sec. 8, cl. 8) of the United States Constitution provides for promoting the progress of science and useful arts by securing for limited times to authors and inventors, the exclusive right to their respective writings and discoveries. (From Black's Law Dictionary, 5th ed, p1014)Foramen Ovale, Patent: A condition in which the FORAMEN OVALE in the ATRIAL SEPTUM fails to close shortly after birth. This results in abnormal communications between the two upper chambers of the heart. An isolated patent ovale foramen without other structural heart defects is usually of no hemodynamic significance.Biotechnology: Body of knowledge related to the use of organisms, cells or cell-derived constituents for the purpose of developing products which are technically, scientifically and clinically useful. Alteration of biologic function at the molecular level (i.e., GENETIC ENGINEERING) is a central focus; laboratory methods used include TRANSFECTION and CLONING technologies, sequence and structure analysis algorithms, computer databases, and gene and protein structure function analysis and prediction.History, 18th Century: Time period from 1701 through 1800 of the common era.Drug Resistance: Diminished or failed response of an organism, disease or tissue to the intended effectiveness of a chemical or drug. It should be differentiated from DRUG TOLERANCE which is the progressive diminution of the susceptibility of a human or animal to the effects of a drug, as a result of continued administration.Blood Gas Monitoring, Transcutaneous: The noninvasive measurement or determination of the partial pressure (tension) of oxygen and/or carbon dioxide locally in the capillaries of a tissue by the application to the skin of a special set of electrodes. These electrodes contain photoelectric sensors capable of picking up the specific wavelengths of radiation emitted by oxygenated versus reduced hemoglobin.Transcutaneous Electric Nerve Stimulation: The use of specifically placed small electrodes to deliver electrical impulses across the SKIN to relieve PAIN. It is used less frequently to produce ANESTHESIA.Disclosure: Revealing of information, by oral or written communication.Puerto Rico: An island in the Greater Antilles in the West Indies. Its capital is San Juan. It is a self-governing commonwealth in union with the United States. It was discovered by Columbus in 1493 but no colonization was attempted until 1508. It belonged to Spain until ceded to the United States in 1898. It became a commonwealth with autonomy in internal affairs in 1952. Columbus named the island San Juan for St. John's Day, the Monday he arrived, and the bay Puerto Rico, rich harbor. The island became Puerto Rico officially in 1932. (From Webster's New Geographical Dictionary, 1988, p987 & Room, Brewer's Dictionary of Names, 1992, p436)Hospitals, Urban: Hospitals located in metropolitan areas.Hispanic Americans: Persons living in the United States of Mexican (MEXICAN AMERICANS), Puerto Rican, Cuban, Central or South American, or other Spanish culture or origin. The concept does not include Brazilian Americans or Portuguese Americans.Hospitals, Municipal: Hospitals controlled by the city government.Drug Delivery Systems: Systems for the delivery of drugs to target sites of pharmacological actions. Technologies employed include those concerning drug preparation, route of administration, site targeting, metabolism, and toxicity.Arachnoid: A delicate membrane enveloping the brain and spinal cord. It lies between the PIA MATER and the DURA MATER. It is separated from the pia mater by the subarachnoid cavity which is filled with CEREBROSPINAL FLUID.Porosity: Condition of having pores or open spaces. This often refers to bones, bone implants, or bone cements, but can refer to the porous state of any solid substance.Defibrillators, Implantable: Implantable devices which continuously monitor the electrical activity of the heart and automatically detect and terminate ventricular tachycardia (TACHYCARDIA, VENTRICULAR) and VENTRICULAR FIBRILLATION. They consist of an impulse generator, batteries, and electrodes.Prostheses and Implants: Artificial substitutes for body parts, and materials inserted into tissue for functional, cosmetic, or therapeutic purposes. Prostheses can be functional, as in the case of artificial arms and legs, or cosmetic, as in the case of an artificial eye. Implants, all surgically inserted or grafted into the body, tend to be used therapeutically. IMPLANTS, EXPERIMENTAL is available for those used experimentally.Radio Frequency Identification Device: Machine readable patient or equipment identification device using radio frequency from 125 kHz to 5.8 Ghz.Electromagnetic Radiation: Waves of oscillating electric and MAGNETIC FIELDS which move at right angles to each other and outward from the source.

The treatment of insulin resistance does not improve adrenal cytochrome P450c17alpha enzyme dysregulation in polycystic ovary syndrome. (1/235)

OBJECTIVE: To determine whether metformin. when given to non-diabetic women with polycystic ovary syndrome (PCOS), results in a reduction of insulin resistance and hyperinsulinemia while body weight is maintained. Also we aimed to see whether the reduction in insulin levels attenuates the activity of adrenal P450c17alpha enzyme in patients with PCOS. DESIGN: We investigated the 17-hydroxyprogesterone (17-OHP) and androstenedione responses to ACTH, insulin responses to an oral glucose tolerance test (OGTT) and glucose disposal rate in an insulin tolerance test before and after metformin therapy (500 mg, orally, twice daily, for 12 weeks). METHODS: The presence of hyperinsulinemia in 15 women with PCOS was demonstrated by an OGTT and results were compared with those of 10 healthy women. Insulin sensitivity was measured by the rate of endogenous glucose disposal after i.v. bolus injection of insulin. 17-OHP and androstenedione responses to ACTH were measured in all the women with PCOS and the normal women. RESULTS: Women with PCOS were hyperinsulinemic (102.0+/-13.0 (S.E.M.) VS 46.2+/-4.4 pmol/l) and hyperandrogenemic (free testosterone 15.3+/-1.7 vs 7.9+/-0.6 nmol/l; androstenedione 11.8+/-0.8 vs 8.2+/-0.6 nmol/l) and more hirsute (modified Ferriman-Gallwey score, 17.7+/-1.6 vs 3.0+/-0.3) than healthy women. In addition, women with PCOS had higher 17-OHP and androstenedione responses to ACTH when compared with healthy women. Metformin therapy resulted in some improvement in insulin sensitivity and reduced the basal and post-glucose load insulin levels. But 17-OHP and androstenedione responses to ACTH were unaltered in response to metformin. CONCLUSIONS: PCOS is characterized by hyperactivity of the adrenal P450c17alpha enzyme and insulin resistance. It seems that there is no direct relationship between insulin resistance and adrenal P450c17alpha enzyme dysregulation.  (+info)

Congenital adrenal hyperplasia: not really a zebra. (2/235)

Congenital adrenal hyperplasia was once considered a rare inherited disorder with severe manifestations. Mild congenital adrenal hyperplasia, however, is common, affecting one in 100 to 1,000 persons in the United States and frequently eluding diagnosis. Both classic and nonclassic forms of the disease are caused by deficiencies in the adrenal enzymes that are used to synthesize glucocorticoids. The net result is increased production from the adrenal gland of cortisol precursors and androgens. Even mild congenital adrenal hyperplasia can result in life-threatening sinus or pulmonary infections, orthostatic syncope, shortened stature and severe acne. Women with mild congenital adrenal hyperplasia often present with hirsutism, oligomenorrhea or infertility. Congenital adrenal hyperplasia is diagnosed by demonstration of excess cortisol precursors in the serum during an adrenal corticotropic hormone challenge. Diagnosis of congenital adrenal hyerplasia in fetuses that are at risk for congenital adrenal hyperplasia can be determined using human leukocyte antigen haplotype or by demonstration of excess cortisol precursors in amniotic fluid. Treatment includes carefully monitored hormone replacement therapy. Recognition of the problem and timely replacement therapy can reduce morbidity and enhance quality of life in patients that are affected by congenital adrenal hyperplasia.  (+info)

The effect of chronic treatment with GH on gonadal function in men with isolated GH deficiency. (3/235)

Eleven adult males, previously submitted to neurosurgery because of a pituitary lesion (three with craniopharyngioma, three with clinically non-functioning adenoma and five with macroprolactinoma) were treated with recombinant GH for 12 months after the diagnosis of GH deficiency was made. Circulating FSH, LH, prolactin, testosterone, 17 beta-estradiol (E2), dehyroepiandrosterone (DHEA-S), androstenedione. 17-OH-progesterone (17OHP), IFG-I, and steroid hormone-binding protein (SHBG) levels were assayed before and after CG test at study entry and 6 and 12 months after GH treatment. A significant increase in plasma IGF-I levels was obtained after 6 and 12 months of GH treatment. In addition, CG-stimulated, but not baseline, testosterone levels showed a significant increase after 6 and 12 months of GH treatment when compared with study entry (9.6 +/- 0.5 and 9.9 +/- 0.5 vs 7.9 +/- 0.5 ng/ml; P < 0.05). Baseline, but not CG-stimulated, serum 17OHP levels were significantly increased only after 12 months of GH treatment (1.7 +/- 0.1 vs 1.4 +/- 0.1 ng/ml; P < 0.05). No significant difference was found as far as both basal and CG-stimulated E2, androstenedione, DHEA-S and SHBG were concerned. With regards to the semen analysis, only seminal plasma volume was significantly increased after 12 months of GH treatment (2.9 +/- 0.3 vs 1.7 +/- 0.3 ml; P < 0.05). No significant change in sperm count, motility and abnormal forms was observed. These data show that GH treatment displays a clear-cut effect upon Leydig cell function and increases the production of seminal plasma volume in fertile adult males with isolated GH deficiency.  (+info)

Ovulatory and metabolic effects of D-chiro-inositol in the polycystic ovary syndrome. (4/235)

BACKGROUND: Women with the polycystic ovary syndrome have insulin resistance and hyperinsulinemia, possibly because of a deficiency of a D-chiro-inositol-containing phosphoglycan that mediates the action of insulin. We hypothesized that the administration of D-chiro-inositol would replenish stores of the mediator and improve insulin sensitivity. METHODS: We measured steroids in serum and performed oral glucose-tolerance tests before and after the oral administration of 1200 mg of D-chiro-inositol or placebo once daily for six to eight weeks in 44 obese women with the polycystic ovary syndrome. The serum progesterone concentration was measured weekly to monitor for ovulation. RESULTS: In the 22 women given D-chiro-inositol, the mean (+/-SD) area under the plasma insulin curve after the oral administration of glucose decreased from 13,417+/-11,572 to 5158+/-6714 microU per milliliter per minute (81+/-69 to 31+/-40 nmol per liter per minute) (P=0.007; P=0.07 for the comparison of this change with the change in the placebo group); glucose tolerance did not change significantly. The serum free testosterone concentration in these 22 women decreased from 1.1+/-0.8 to 0.5+/-0.5 ng per deciliter (38+/-7 to 17+/-3 pmol per liter) (P=0.006 for the comparison with the change in the placebo group). The women's diastolic and systolic blood pressure decreased by 4 mm Hg (P<0.001 and P=0.05, respectively, for the comparisons with the changes in the placebo group), and their plasma triglyceride concentrations decreased from 184+/-88 to 110+/-61 mg per deciliter (2.1+/-0.2 to 1.2+/-0.1 mmol per liter) (P=0.002 for the comparison with the change in the placebo group). None of these variables changed appreciably in the placebo group. Nineteen of the 22 women who received D-chiro-inositol ovulated, as compared with 6 of the 22 women in the placebo group (P<0.001). CONCLUSIONS: D-Chiro-inositol increases the action of insulin in patients with the polycystic ovary syndrome, thereby improving ovulatory function and decreasing serum androgen concentrations, blood pressure, and plasma triglyceride concentrations.  (+info)

Adrenal 21-hydroxylase gene mutations in Slovenian hyperandrogenic women: evaluation of corticotrophin stimulation and HLA polymorphisms in screening for carrier status. (5/235)

OBJECTIVE: To study the incidence of 21-hydroxylase deficiency in Slovenian hyperandrogenic women, at the gene level. Previous endocrine studies indicated large differences in the incidence of 21-hydroxylase deficiency in hyperandrogenic women. The predictive values of the 17-hydroxyprogesterone (17-OHP) response to ACTH stimulation and of HLA typing in screening for carrier status were re-evaluated. DESIGN: Molecular analysis of CYP21 gene, ACTH stimulation and human leucocyte antigen (HLA) typing were performed in 83 consecutive Slovenian hyperandrogenic women. MEASUREMENTS: Cortisol and 17-OHP concentrations were measured at baseline and 60 min after ACTH stimulation. Basal adrenal androgen concentrations were also measured. RESULTS: None of 83 hyperandrogenic patients was affected with non-classical 21-hydroxylase deficiency, but 12 of 81 patients (14.8%) had high concentrations of 17-OHP after stimulation, indicative of carrier status. The increase in 17-OHP concentrations could be explained by a carrier status for CYP21 gene mutations in only three of 12 patients (25%), whereas seven of 69 patients (10. 1%) with normal concentrations of 17-OHP after stimulation were found to be carriers of CYP21 gene mutations, indicating low positive predictive values of ACTH stimulation as a screening test for carriers of 21-hydroxylase deficiency. In total, 11 carriers were identified among 83 patients: seven CYP21 gene deletions/conversions, two Gln(318)Stop and one Val(281)Leu mutation and one gene conversion extending from exon 4 to exon 7 were found. The association between Val(281)Leu mutation and HLA-B14 antigen was confirmed in this Slovenian population. CONCLUSIONS: Basal or ACTH-stimulated 17-OHP concentrations are not a good indicator of the carrier status for 21-hydroxylase deficiency among Slovenian hyperandrogenic patients. Reliable screening for carriers of 21-hydroxylase deficiency is possible only by molecular analysis of the CYP21 gene.  (+info)

Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. (6/235)

The aim of this study was to examine the echocardiographic profiles of patients with polycystic ovarian syndrome (PCOS). Serum concentrations of follicle stimulating hormone, luteinizing hormone, androstenedione, free testosterone, prolactin, DHEA-SO(4) and 17-OH-progesterone, lipid profile (high and low density lipoproteins, triglyceride and total cholesterol) and basal and total insulin after a glucose tolerance test were measured in 35 patients with PCOS and 35 healthy controls matched for body mass index. Doppler, two dimensional M mode echocardiography was performed for the following indices: isovolumetric relaxation time (IVRT), E wave duration time (EVT), A wave duration time (AVT), E wave deceleration time (DT), peak early diastolic flow velocity (PEV), peak late diastolic flow velocity (PAV), E wave velocity time integral (FVI-E), A wave velocity time integral (FVI-A), atrial filling fraction (AFF), ejection fraction (EF), pre-ejection time (PEP), ejection time (ET) and aortic flow velocity time integral (FVI). Androstenedione, free testosterone, low density lipoproteins and cholesterol concentrations were significantly higher in patients with PCOS. There was no difference in basal and total insulin concentrations. IVRT, AVT, FVI-A, AFF, and PEP were higher in patients with PCOS, while PEV, FVI-E, EF, ET, EVT and EVT/AVT were higher in the control group. There was a positive correlation between basal insulin values and IVRT, and between total insulin values and EF. These changes are consistent with a non-restrictive type of diastolic dysfunction and left ventricular stiffness. PCOS may lead to diastolic dysfunction via hyperinsulinaemia and male type dyslipidaemia.  (+info)

Aortic plaque size and endometrial response in cholesterol-fed rabbits treated with estrogen plus continuous or sequential progestin. (7/235)

ERT is associated with a reduced incidence of coronary risk and cardiac events in postmenopausal women, but increases the risk of endometrial hyperplasia and carcinoma. Combined estrogen and progestin therapy protects the endometrium; however, its effects on heart disease risk factors are not completely known. In our study, 56 ovariectomized New Zealand White rabbits in 7 groups received a 0.5% cholesterol diet for 12 weeks. Controls were not treated with hormones. All other animals received (per kilogram body weight per week) intramuscular injections of either 0.3 mg estrogen (estradiol valerate) alone, 8.3 mg progestin (hydroxyprogesterone caproate) alone, estrogen and progestin continuously in 3 different dosages (0.3 and 8.3 mg; 1 and 8.3 mg; or 1 and 2.8 mg; estrogen and progestin, respectively), or 1 mg estrogen with 25 mg progestin sequentially in 2-week cycles. Eight non-ovariectomized animals served as further controls for endometrial analysis. Morphometric analysis of plaque size in the aortic arch showed that estrogen monotherapy, and the 3 combined therapies with 1 mg estrogen, significantly reduced intimal thickening (P<0.05). The application of progestin alone had no effect on plaque size. The endometrium was enlarged by 3-fold after estrogen treatment, and was decreased by half after progestin treatment, compared with control uteri (P<0.05). In all groups with combined hormone regimens, endometrial size was not significantly different from control uteri. However, these uteri showed more inflammatory reactions, especially when higher doses of hormones were given. In this animal model, doses of progestin that are able to successfully reduce the proliferative effect of estrogen on endometrium do not diminish the desirable antiatherosclerotic properties of estrogen.  (+info)

Longitudinal measurements of 17alpha-hydroxyprogesterone in premature infants during the first three months of life. (8/235)

AIMS: To determine normal concentrations of 17alpha-hydroxyprogesterone (17OHP) for premature infants. METHODS: 17OHP was measured in 66 consecutive premature infants once a week during the first month, and once every two weeks thereafter, until the age of 3 months. The 17OHP values in 100 full term healthy neonates on the third day of life served as controls. Blood was sampled on filter paper using a neonatal radioimmunoassay kit. Findings were correlated with gestational age, birthweight, mode of delivery, Apgar scores, presence of respiratory distress syndrome and intake of maternal steroids. RESULTS: Mean 17OHP was raised at 7 days of age (138.9, 46.3, 53.3, 29.9 nmol/l, respectively, for infants whose gestational age was under 29 weeks, 29 to 30 weeks, 31 to 32 weeks, and 33 weeks and above). It fell sharply in the first two weeks after which it gradually decreased further, reaching 32.7, 23.6, 16.9, and 13.0 nmol/l, respectively, by the age of 90 days. The mean (SEM) 17OHP concentration in full term infants on day 3 of life was 17.8 (8.9) nmol/l. These values were independent of the presence and severity of respiratory distress syndrome and of prenatal maternal steroids. CONCLUSIONS: The increased 17OHP concentrations found at birth fell to those found in term infants during the first three months of life in infants over 31 weeks of gestation. Postconceptional age is the most important factor determining 17OHP concentration.  (+info)

Definition of 17-alpha-hydroxyprogesterone in the Definitions.net dictionary. Meaning of 17-alpha-hydroxyprogesterone. What does 17-alpha-hydroxyprogesterone mean? Information and translations of 17-alpha-hydroxyprogesterone in the most comprehensive dictionary definitions resource on the web.
hydroxyprogesterone - MedHelps hydroxyprogesterone Center for Information, Symptoms, Resources, Treatments and Tools for hydroxyprogesterone. Find hydroxyprogesterone information, treatments for hydroxyprogesterone and hydroxyprogesterone symptoms.
Hydroxyprogesterone is a form of progestin, a manmade form of a female hormone called progesterone. Hydroxyprogesterone is used to lower the risk of premature birth in a woman who has already had one premature baby. This medication will not stop premature labor that has already begun. Hydroxyprogesterone is not for...
Describes how the 17-hydroxyprogesterone (17-OHP) test is used, when a 17-OHP test is ordered, and what the results of a 17-hydroxyprogesterone test might mean
The reference range of urinary 17-hydroxyprogesterone (17-OHPG) in children is as follows: Age 3 days to 1 year: Up to 50 ng/24 hours Age 1-8 years: Up to 300 ng/24 hours The following is the reference of urinary 17-OHPG in adults: Males: Up to 2 µg/24 hours Females: Up to 4.5 µg/24 hours .
... ,ARUP Laboratories is a national reference laboratory and a worldwide leader in innovative laboratory research and development. ARUP offers an extensive test menu of highly complex and unique medical tests in clinical and anatomic pathology. Owned by the University of Utah, ARUP Laboratories client,medicine,medical supply,medical supplies,medical product
Manufacturer of Gynae Pharma Franchise - Hydroxyprogesterone Injection ( Myterm -H 500 ) Inj, Gynae PCD Pharma Franchise offered by Corazon (A Division Of Arlak Biotech Private Limited), Zirakpur, Punjab.
Gonadectomized male rats of Wistar strain were administered 3H-progesterone. Various brain tissues and anterior pituitary were analyzed for retention of radioactivity, using a liquid scintillation technique. Radioactivity, in all tissues, was highe
In addition to the 17-OH-Progesterone (OHP), we are now able to offer an expanded adrenal steroid hormone profile which includes Cortisol, OHP, Progesterone, E2, Testosterone and Androstenedione. This gives a complete picture of the adrenal status.. A standard ACTH stimulation test (see p22) should be performed. At least 2 mLs of serum or plasma is required to carry out all the analysis.. ...
Progesterone + [Reduced NADPH---hemoprotein reductase] + Oxygen ,=> 17alpha-Hydroxyprogesterone + [Oxidized NADPH---hemoprotein reductase] + ...
EIAab can provide you General 17-Hydroxyprogesterone ELISA Kit(General 17OHP ELISA Kit) with more favourable price and high quality.
Background: 42 y/o No aas or pro hormone history 61 200lbs Lift 4 times/week 2 push 2 pull Push: 6 sets 8 ohp 6 sets 8 dips (forward lean) 6 sets 8
11β-Hydroxyprogesterone (11β-OHP), also known as 21-deoxycorticosterone, as well as 11β-hydroxypregn-4-ene-3,20-dione, is a naturally occurring, endogenous steroid and derivative of progesterone. It is a potent mineralocorticoid. Increased levels of 11β-OHP occur in 21-hydroxylase deficiency. Along with its epimer 11α-hydroxyprogesterone (11α-OHP), 11β-OHP has been identified as a very potent competitive inhibitor of both isoforms (1 and 2) of 11β-hydroxysteroid dehydrogenase (11β-HSD). 21-Deoxycortisol (11β,17α-dihydroxyprogesterone) 11-Deoxycorticosterone (21-hydroxyprogesterone) Corticosterone (11β,21-dihydroxyprogesterone) Cortisol (11β,17α,21-trihydroxyprogesterone) 11-Deoxycortisol (17α,21-dihydroxyprogesterone) 9α-Bromo-11-ketoprogesterone "Human Metabolome Database: Showing metabocard for 11b-Hydroxyprogesterone (HMDB04031)". hmdb.ca. Retrieved 2016-12-16. Souness GW, Latif SA, Laurenzo JL, Morris DJ (1995). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of ...
11α-Hydroxyprogesterone (11α-OHP), or 11α-hydroxypregn-4-ene-3,20-dione is an endogenous steroid and metabolite of progesterone. It is a weak antiandrogen, and is devoid of androgenic, estrogenic, and progestogenic activity. It was investigated as a topical antiandrogen for the treatment of androgen-dependent skin conditions in the early 1950s, and was found to produce some benefit. In 1995, 11α-OHP, along with its epimer 11β-hydroxyprogesterone, was identified as a very potent competitive inhibitor of both isoforms (1 and 2) of 11β-hydroxysteroid dehydrogenase (11β-HSD). It is notably not metabolized by 11β-HSD2. 11α-OHP is a more potent inhibitor of 11β-HSD than enoxolone (glycyrrhetinic acid) or carbenoxolone in vitro (IC50 = 0.9 nM; IC50 = 5 nM in transfected cells). The compound has been found to be highly active in conferring mineralocorticoid sodium-retaining activity of corticosterone in vivo in rat bioassays and in increasing blood pressure, effects that it mediates by ...
The 17-hydroxyprogesterone test is mainly used to check for the most common form of the genetic disorder congenital adrenal hyperplasia (CAH) in infants and children.
Cookies are important for the proper functioning of a website. In order to improve your experience, we use cookies to keep the login information and provide a secure connection, collect the statistics to optimize the functionality of the website and adapt the content to your interests. Click on "Accept and Continue" to accept cookies and access to the website or you can refer to our Privacy Policy.. ...
Disease, Amyloid, Biomarkers, Growth, Role, Cerebrospinal Fluid, Threonine, Fibroblast Growth Factor, Hormone, Methods, Measure, 17-hydroxyprogesterone, Congenital Adrenal Hyperplasia, Development And Growth, Hormones, Hyperplasia, Meningiomas, Progesterone, Progesterone Receptors, Quality Control
A microsomal cytochrome P-450 (heme-thiolate) protein that catalyses two independent reactions at the same active site - the 17-hydroxylation of pregnenolone and progeste
Describes how the androstenedione test is used, when an androstenedione test is ordered, and what the results of an androstenedione test might mean
מאמרים (כתבות) עם התגית androstenedione: 57(1) Full article PDF, 59(1) Full article PDF, Contents of 57(1), 2005, Contents of 59(1), 2007, ועוד...
Biochemistry;Hydroxyketosteroids;Steroids;Steroid and Hormone;Hormone Drugs, Hydroxyprogesterone caproate - Drug, 17 hydroxyprogesterone caproate, 17 hydroxyprogesterone, hydroxyprogesterone caproate injection, alpha hydroxyprogesterone caproate, 17 alpha hydroxyprogesterone, massachusetts veterinarian, hydroxyprogesterone, massachusetts veterinarians, hydroxy progesterone,
We offer to book Congenital Adrenal Hyperplasia (CAH) Test online for Newborn Screening. View Congenital Adrenal Hyperplasia (CAH) Test cost, pre test information and report availability on trutestlab.com. Home collection of blood sample is also available at our centers.
3. Androgens, which are responsible for the development of secondary sexual characteristics (adrenarche) in both males and females.. All three of these adrenal hormones are necessary for normal body functioning in both males and females. In patients with Congenital Adrenal Hyperplasia, the adrenal glands typically produce too little cortisol and aldosterone, while producing too much of the androgen hormones. Excess levels of androgens can cause atypical genitalia, growth abnormalities, early puberty, and problems with fertility. All infants born in the United States are screened for Congenital Adrenal Hyperplasia shortly after birth. If your child is diagnosed with Congenital Adrenal Hyperplasia, additional tests including blood tests and imaging tests, such as X-rays or ultrasounds, are often done. Ultimately, genetic testing is used to confirm the diagnosis.. CAH is a condition that requires long-term follow-up and monitoring. The treatment involves life-long cortisol with or without ...
Get information, facts, and pictures about Congenital adrenal hyperplasia at Encyclopedia.com. Make research projects and school reports about Congenital adrenal hyperplasia easy with credible articles from our FREE, online encyclopedia and dictionary.
Introduction: 21-Hydroxylase deficiency is the most frequent form of congenital adrenal hyperplasia (CAH) which is a common autosomal recessive disorder characterized by impaired adrenocortical and adrenomedullary function, and adrenal hyperandrogenism. Chronic glucocorticoid therapy and excess androgen exposure in patients with CAH may predispose them to developing a metabolic syndrome in adulthood.Our objective is to evaluate the metabolic syndrome in adulthood in a Tunisian cohort.. Subjects and Methods: We underwent a prospective study of 26 patients over 16 years of old with CAH.. Results: The cases included 26 patients (M: 11, F: 15) with CAH due to 21-hydroxylase deficiency with a mean age of 27.4 years (16.5-48 years). Eighteen patients had the classical CAH form and the remaining 8 patients had the non-classical form. The mean body mass index was 26,9 ± 4,27 kg/m2 (20,3-34,8 kg/m2). The most commonly used drug was hydrocortisone which was used by 21 cases. Five cases had been managed ...
Defective conversion of 17-hydroxyprogesterone to 11-deoxycortisol accounts for more than 90 percent of cases of congenital adrenal hyperplasia (CAH). This conversion is mediated by 21-hydroxylase, the enzyme encoded by theCYP21A2gene.Patients with c
TY - JOUR. T1 - Stigma in medical settings as reported retrospectively by women with Congenital Adrenal Hyperplasia (CAH) for their childhood and adolescence. AU - Meyer-Bahlburg, Heino F.L.. AU - Khuri, Jananne. AU - Reyes-Portillo, Jazmin. AU - New, Maria I.. PY - 2017/1/1. Y1 - 2017/1/1. N2 - Objectives To perform a qualitative study of stigma experienced in medical settings by children and adolescents with congenital genital ambiguity (CGA). Methods 62 women with classical congenital adrenal hyperplasia (CAH) of variable severity took part in a qualitative retrospective interview that focused on the impact of CAH and its medical treatment, with an emphasis on childhood and adolescence. Categorization of stigmatization was based on deductive content analysis of the interview transcripts. Results Many women recalled experiencing the genital examinations in childhood and adolescence as adverse, stigmatizing events, leading to avoidance reactions and self-perception as abnormal, particularly ...
There is no clear consensus among state newborn screening programs on whether routine second screening of newborns identifies clinically relevant cases of congenital adrenal hyperplasia. This retrospective study evaluated laboratory practices, along with biochemical and medical characteristics of congenital adrenal hyperplasia (CAH) cases (1) detected on the first newborn screen in one-screen compared to two-screen states, and (2) detected on the first versus the second screen in the two-screen states, to determine the effectiveness of a second screen. A total of 374 confirmed cases of CAH from 2 one-screen states and 5 two-screen states were included in this study. Demographic data and diagnostic information on each reported case were collected and analyzed. Additionally, laboratory data, including screening methodologies and algorithms, were evaluated. The one-screen states reported 99 cases of CAH out of 1,740,586 (1 in 17,500) newborns screened: 88 (89%) identified on the first screen and 5 ...
Congenital Adrenal Hyperplasia in males (CAH), symptoms, causes and treatment of Congenital Adrenal Hyperplasia, parents should always get themselves treated in all manner of conditions before going ahead to bear children.
To determine the glucocorticoid receptor (GC-R) status in congenital adrenal hyperplasia (CAH) we examined 11 patients (5 female, 6 male) with 21-hydroxylase deficiency and 3 patients (2 female, 1 male) with 11 beta -hydroxylase deficiency, The mean age at investigation was 8.9+/-3.5 yr, Age of diagnosis was 4.4+/-3.2 yr and all patients were being treated with hydrocortisone, The control group included 10 (5 female, 5 male) age-matched healthy children. Blood samples were drawn at 0800 a.m. after an overnight fast in all subjects and after 5 days off treatment in patients with CAH. Serum cortisol tin all children), and serum 17-hydroxyprogesterone and androstenedione tin the patient group) were measured by radioimmunoassay, Mononuclear leukocytes were isolated from peripheral blood and the binding of [H-3]dexamethasone to GC-R was examined. GC-R number and the dissociation constant (Kd), which is inversely proportional to its binding affinity, were determined, Mean GC-R numbers were 5814+/-1574 ...
CAH21 : Preferred screening test for congenital adrenal hyperplasia (CAH) that is caused by 21-hydroxylase deficiency   Part of a battery of tests to evaluate females with hirsutism or infertility, which can result from adult-onset CAH
Congenital adrenal hyperplasia (CAH) is a common genetic endocrine disorder, with 21-hydroxylase enzyme deficiency accounting for 95% of the cases. 21-hydroxylase deficiency presents with a spectrum of clinical manifestations ranging from salt-wasting and virilization of female neonates (classic CAH) to symptomatic (precocious puberty, short stature, acne) or asymptomatic hyperandrogenemia (non-classic CAH). Classic CAH is characterized by impaired cortisol and mineralocorticoid biosynthesis, which triggers adrenocorticotropic hormone (ACTH) hyper-secretion and accumulation of adrenal androgens. Glucocorticoid treatment of patients with classic CAH focuses on cortisol replacement and prevention of the ACTH-driven androgen excess. Current conventional glucocorticoid treatment regimens (short or long-acting agents dosed once, twice or thrice daily) have failed to simulate physiological cortisol secretion and suppress adrenal androgen overproduction, without supraphysiologic replacement. Short-term ...
Background: Newborn screening for congenital adrenal hyperplasia (CAH) is based on the determination of 17-hydroxyprogesterone (17OHP) on blood and its need is confirmed by the most recent guidelines on the subject. In Italy this screening is not mandatory, and its application is on a regional basis. Among its disadvantages, it is well known the high frequency of false-positives, in particular in premature babies and those born small for gestational age. However, there are a number of subjects who are false-negatives (FN), with the risk of late diagnosis and development of complications.. Case report: A 4-year-old boy presented with pubic hair, body odor and acne noted one year earlier. At clinical examination, height was 125.1 cm (+3.85 SDS, target height +0,70 SDS), weight 25,1 kg (+2 SDS) and he had mild acne in his face. He was Tanner stage 2 (G2PH3, testicular volume 4 ml bilaterally). Bone age was 12-13 years. In his previous medical history, he was recalled for CAH screening performed at ...
This thread is over a year old but I thought I would check in on you. How are you now? Here is something that may help with what your dealing with. Im 43 years old and a female in 1993 I was diagnosed with Congenital Adrenal Hyperplasia 21 OH deficiency I had a stress dose of cortisol for adrenal crisis and was sent home with no other instructions. Being a young mother and ignorant of this condition I thought it was a one time event and tried to move on with my life. Needless to say for twenty some odd years I had no idea I was in trouble. I had an ACTH stimulation test that showed a morning cortisol of 16 the 17 hydroxyprogesterone level was 10,900 at thirty minutes. I asked for an adrenal washout CT scan and it showed a .09 x 1.3 cm growth on my left adrenal gland. These can produce excess cortisol but is you are CAH 21 OH deficient you cant use it and full physiologic replacement should be given. I recommend Dr Maria New at Mount Sanai hospital in New York she is an expert in ...
Congenital adrenal hyperplasia (CAH) is caused by the genetic impairment of one of the five enzymes required for the biosynthesis of cortisol from cholesterol. In 95% of cases 21-hydroxylase deficiency (21-OHD) is responsible for the disease (1). Classic 21-OHD has an incidence varying from 1:11 800 to 1:21 800, depending on the population background. The pathophysiology, clinical picture, genetics, and the unique aspects of management from the point of view of the paediatric endocrinologist are addressed, and the problems encountered from birth to puberty are described. The child specific issues of rare forms of CAH are summarized thereafter. The reader is referred to Chapter 5.11 for a comprehensive overview of 21-OHD and for more details on all other forms of CAH.. ...
Congenital adrenal hyperplasia (CAH) is a problem that affects how the adrenal glands work. The adrenal glands need an enzyme to make certain hormones. Children with CAH are missing or have low levels of this enzyme.. The hormones produced by the adrenal glands affect nearly every organ in the body. They help the body cope with stress, hold salt and water, and maintain blood pressure. They also affect sexual development.. CAH is a problem that is passed through genes. Most of the time its found during routine newborn blood tests.. When a child has CAH, he or she will need to take medicine each day to replace the missing hormones.. You may have just learned that your baby has CAH. You will get more information and support from the hospital staff. ...
Molecular Identification of Intron 2 Splice Mutation and 8bp Deletion in CYP21 Gene for Congenital Adrenal Hyperplasia (CAH) Patients in Kashmir (North India) Abstract.
Congenital Adrenal Hyperplasia causes a cortisol deficiency in infants, children and adolescents and can be treated by Pediatric Endocrine Associates
Female patients with congenital adrenal hyperplasia have been frequently studied in order to determine the impact of prenatal androgen exposure on various aspects of psychological, psychosocial and...
Doctors at Hassenfeld Childrens Hospital at NYU Langone diagnose classic and nonclassic types of congenital adrenal hyperplasia in children. Read more.
An education and support network for people and families with Congenital Adrenal Hyperplasia. Includes important medical links, FAQ, Message Board and Archives.
An education and support network for people and families with Congenital Adrenal Hyperplasia. Includes important medical links, FAQ, Message Board and Archives.
TY - JOUR. T1 - Congenital adrenal hyperplasia. AU - White, P. C.. AU - New, M. I.. AU - Dupont, B.. PY - 1987. Y1 - 1987. UR - http://www.scopus.com/inward/record.url?scp=0023226909&partnerID=8YFLogxK. UR - http://www.scopus.com/inward/citedby.url?scp=0023226909&partnerID=8YFLogxK. M3 - Article. C2 - 3295546. AN - SCOPUS:0023226909. VL - 316. SP - 1580. EP - 1586. JO - New England Journal of Medicine. JF - New England Journal of Medicine. SN - 0028-4793. IS - 25. ER - ...
17a-Hydroxypogesterone (17aOHP) is a steroid intermediate in the biosynthesis of glucocorticoids. It is produced in the testes, ovary and adrenal. The main clinical use of this assay is in the diagnosis and monitoring of congenital adrenal hyperplasia due to 21-hydroxylase deficiency.. ...
Another name for Adrenal Hyperplasia is Congenital Adrenal Hyperplasia. Treatment for congenital adrenal hyperplasia usually includes hormone therapy ...
There are two types of CAH. The first called Classical CAH which is usually detected through prenatal testing or diagnosed in early childhood. When the pituitary gland senses there is insufficient cortisol in the bloodstream, it releases a hormone called ACTH (adrenocorticotropic hormone). This, in turn, stimulates the adrenals to produce more cortisol. The enzyme 21-hydroxylase is needed to convert a precursor molecule called 17-hydroxyprogesterone (17-OHP) into cortisol, but those with CAH lack sufficient amounts of 21-hydroxylase causing the pituitary gland to pump out more ACTH when it senses the need for cortisol. The adrenals convert an overabundance of 17-OHP into masculine steroid hormones called androgens. As stated before, adrenal glands are responsible for creating cortisol, in order to maintain adequate energy supply and blood sugar levels, and deal with physical and emotional stress. "Lack of adequate cortisol also prevents the body from properly metabolizing sugar and responding to ...
7-hydroxyprogesterone: formed by the hydroxylation of progesterone by extracts of Phycomyces blakesleeanus; RN given refers to (alpha)-isomer; RN for cpd without isomeric designation not avail 4/91
11β-hydroxylase deficiency (11β-OHD), an autosomal recessive inherited disorder, accounts for 5-8% of congenital adrenal hyperplasia. In Greece, no cases of 11β-OHD have been described so far. The patient presented at the age of 13 months with mild virilization of external genitalia and pubic hair development since the age of 3 months. Hormonal profile showed elevated 11-deoxycortisol, adrenal androgens and ACTH levels. ACTH stimulation test was compatible with 11β-OHD. DNA of the proband and her parents was isolated and genotyped for CYP11B1 gene coding cytochrome P450c11. The girl was found to be compound heterozygous for two CYP11B1 novel mutations, p.Ala386Glu (exon 7), inherited from the father and p.Leu471Argin (exon 9) from the mother. Hydrocortisone supplementation therapy was initiated. Four years after presentation she remains normotensive, her growth pattern is normal and the bone age remains advanced despite adequate suppression of adrenal androgens. ...
Congenital adrenal hyperplasia (CAH) is a genetic disorder arising from defective steroidogenesis resulting in glucocorticoid deficiency; the commonest mutation is in the gene encoding 21-hydroxylase. Lifesaving glucocorticoid treatment was introduced in the 1950s and there is now an enlarging cohort of adult patients; however, there is no consensus on management. To address this issue, the Congenital adrenal Hyperplasia Adult Study Executive (CaHASE) was formed in 2003 to study the health status of CAH patients in adulthood. Seventeen specialist Endocrinology centres around the United Kingdom recruited a cohort of 203 adult patients and gathered information on medical treatment, fertility, genetic analysis and quality of life (QoL). The CaHASE study found that adult patients are prescribed a variety of glucocorticoids including hydrocortisone, prednisone, prednisolone, dexamethasone, and combinations taken in either a circadian or reverse circadian regimen. Despite this variety in personalized ...
With careful treatment it should be possible for children with CAH to grow at a rate sufficient to achieve an adult height within the normal range. However, even with the very best treatment, it is not always possible to achieve perfect growth in CAH, and some individuals may end up shorter adults than they would otherwise have been. Also, the dose of hydrocortisone required to control the CAH may make it difficult for some children to keep their weight down, and this can be a particular problem for girls at adolescence. It may be helpful to have the input of a dietician - you should discuss this with your specialist. ...
With careful treatment it should be possible for children with CAH to grow at a rate sufficient to achieve an adult height within the normal range. However, even with the very best treatment, it is not always possible to achieve perfect growth in CAH, and some individuals may end up shorter adults than they would otherwise have been. Also, the dose of hydrocortisone required to control the CAH may make it difficult for some children to keep their weight down, and this can be a particular problem for girls at adolescence. It may be helpful to have the input of a dietician - you should discuss this with your specialist. ...
An inherited condition that affects the adrenal glands. These glands are located on top of the kidneys and produce three types of hormones called cortisol, aldosterone and androgens. Females with classical CAH are born with masculine appearing external genitals but with female internal sex organs. Males with classical CAH appear normal at birth. Males and females with classical CAH are likely to have trouble retaining salt, a condition that can be life threatening.
Adrenal gland- ito ay isang organ na matatagpuan sa ibabaw ng kidneys. Ito ang gumaganap upang magbigay ng hormones na kinakailangan ng katawan para sa normal function. Ang mga hormones na lumalabas sa adrenal glands ay cortisol , aldosterone at androgen. ...
Cardiology news, research and treatment articles offering cardiology healthcare professionals cardiology information and resources to keep them informed.
Dr. Alan Jacobs has helped many patients with anxiety disorders caused by adrenal issues, including the woman in this case study.
Поздние осложнения классической формы врожденной дисфункции коры надпочечников и ее неадекватного лечения у мужчин (клинический случай с обзором литературы)
You can manage your cookie settings via your browser at any time. To learn more about how we use cookies, please see our cookies policy. ...
We offer clinical cancer updates, treatment guidance, and research news to the oncology nursing community. Visit us often for drug therapy testing results, patient care information and more. Download our FREE app today.
Disclaimer: The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the users own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer ...
Children. Preterm infants. Preterm infants may exceed 630 ng/dL, however, it is uncommon to see levels reach 1,000 ng/dL.. Term infants. 0-28 days: ,630 ng/dL. Levels fall from newborn (,630 ng/dL) to prepubertal gradually within 6 months.. Prepubertal males: ,110 ng/dL. Prepubertal females: ,100 ng/dL Adults. Males: ,220 ng/dL. Females. Follicular: ,80 ng/dL. Luteal: ,285 ng/dL. Postmenopausal: ,51 ng/dL. Note: For pregnancy reference ranges, see: Soldin OP, Guo T, Weiderpass E, et al: Steroid hormone levels in pregnancy and 1 year postpartum using isotope dilution tandem mass spectrometry. Fertil Steril 2005 Sept;84(3):701-710. ...
[Determination of serum steroids in monitoring therapy of congenital adrenal hyperplasia].: Each of serum 17-OHP or/and Δ4-A concentration was of significance i
Chronocort vs. Cortef Cortisol Concentrations (AUC Over 24 Hours - Time Points 0,.5,1,1.5,2,3,4,5,6,7,8,10,10.5,11, 11.5,12,13,15,17,17.5,18,18.5,19,20,22,24 Post Dose ...
Texas mandates a two-test newborn screening program for congenital adrenal hyperplasia (CAH): one test at birth and a second test at approximately one to two weeks after birth. The authors compared the dollar cost of detecting infants with CAH clinic ...
In this thesis several important proteins are investigated from a structural perspective. Some of the proteins are disease related while other have important but not completely characterised functions. The techniques used are general as demonstrated by applications on metabolic proteins (CYP21, CYP11B1, IAPP, ADH3), regulatory proteins (p53, GDNF) and a transporter protein (ANTR1).. When the protein CYP21 (steroid 21-hydroxylase) is deficient it causes CAH (congenital adrenal hyperplasia). For this protein, there are about 60 known mutations with characterised clinical phenotypes. Using manual structural analysis we managed to explain the severity of all but one of the mutations. By observing the properties of these mutations we could perform good predictions on, at the time, not classified mutations.. For the cancer suppressor protein p53, there are over thousand mutations with known activity. To be able to analyse such a large number of mutations we developed an automated method for evaluation ...
Lipoid congenital adrenal hyperplasia (LCAH) is considered to be potentially life-threatening unless treated in early infancy; see links at STAR gene and via ClinVar. ...
Diagnosis of patients with even mild hirsutism should include assessment of ovulation and ovarian ultrasound , due to the high prevalence of polycystic ovary syndrome (PCOS) , as well as 17α-hydroxyprogesterone (because of the possibility of finding
TY - JOUR. T1 - DOT‐17α‐HYDROXYPROGESTERONE RADIOIMMUNOASSAY FOR IDENTIFICATION OF CONGENITAL ADRENAL HYPERPLASIA IN YOUNG INFANTS. AU - SÓLYOM, J.. AU - HERVEI, SAROLTA. AU - MAROSSY, P.. AU - SóLYOM, ENIKö. AU - BABOSA, MÁRIA. AU - SZOMBATHY, G.. PY - 1981/12. Y1 - 1981/12. N2 - Abstract. Sólyom, J., Hervci, S., Marossy, P., Sólyom, E., Babosa, M. and Szombathy, G. (2nd Dept. of Paediatrics, Semmelweis Med. Univ., Budapest, Childrens Hosp., Miskolc, "Heim Pál" Childrens Hosp., Budapest, County Hosp., Paediatric Dept., Nyiregyháza; Hungary). Dot‐17α‐hydroxyprogesterone radioimmunoassay for identification of congenital adrenal hyperplasia in young infants. Acta Paediatr Scand, 70: 913, 1981.‐Using a simplified radioimmunoassay method for the determination of 17‐hydroxyprogesterone (17‐OHP) concentration in blood dried on filter paper seven untreated cases of congenital adrenal hyperplasia were identified among newborns and infants at risk for congenital adrenal ...
Use of TaqI digestion may lead to incorrect molecular diagnosis of congenital adrenal hyperplasia due to 21-hydroxylase deficiency ...
The clinical manifestations of CAH in adults result from adrenocortical and adrenomedullary insufficiency, hyperandrogenism, and the adverse effects of glucocorticosteroids used for the treatment of the condition. Non-classic CAH may sometimes be asymptomatic. In patients with classic CAH obesity, hyperinsulinaemia, insulin resistance, and hyperleptinaemia are more often seen than in the general population. These abnormalities promote the development of metabolic syndrome and its sequelae, including endothelial dysfunction, and cardiovascular disease. Long-term glucocorticosteroid treatment is also a known risk factor for osteoporosis ...
The majority of congenital adrenal hyperplasia (CAH) cases arise from mutations in the steroid 21-hydroxylase (CYP21) gene. Without reliance on HLA gene linkage analysis, we have developed primers for differential polymerase chain reaction (PCR) amplification of the CYP21 gene and the non-functional CYP21P gene. Using the amplification created restriction site (ACRS) approach for direct mutational detection, a secondary PCR was then performed using a panel of primers specific for each of the 11 known mutations associated with CAH. Subsequent restriction analysis allowed not only the detection but also the determination of the zygosity of the mutations analysed. Existing deletion of the CYP21 gene could also be detected. In the analysis of 20 independent chromosomes in 11 families of CAH patients in Taiwan, four CYP21 mutation types, besides deletion, were detected. Interestingly, in five different alleles, the CYP21P pseudogene contained some polymorphisms generally associated with the CYP21 ...
Evaluation of Blood Pressure and Left Ventricular Parameters in Children with Classical Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency: An Egyptian Experience Abstract.
Congenital adrenal hyperplasia (CAH), also known as the "adrenogenital syndrome," is an uncommon condition caused by a congenital defect in one of several enzymes that take part in the chain of reactions whereby cortisol is manufactured from its precursors. There are at least six fairly well-defined variants of CAH that result from the various enzyme defects. The most common of these are types I and II, which are due to C21-hydroxylase enzyme deficiency. All CAH variants are inherited as autosomal recessive traits. The clinical and laboratory findings depend on which metabolic pathway-and which precursor in the metabolic pathway- is affected. All variants affect the glucocorticoid (cortisol) pathway in some manner. In CAH due to 21-hydroxylase defect (types I and II) and in CAH type III, although formation of cortisone and cortisol is blocked, the precursors of these glucocorticoids are still being manufactured. Most of the early precursors of cortisone are estrogenic compounds, which also are ...
Learn about Congenital Adrenal Hyperplasia (CAH) symptoms and causes from experts at Boston Childrens, ranked best Childrens Hospital by US News.
The details of bibliography - Ethnic and gender differences in rates of congenital adrenal hyperplasia in Western Australia over a 21 year period
AMH levels correlated with SDAST and GnRHag test outcomes. AMH was elevated (,6.2 ng/mL) in 32% of V-PCO versus 5% V-NO. The 21% of V-PCO who met Rotterdam PCOS criteria all had functional ovarian hyperandrogenism, but AMH levels were similar to nonhyperandrogenic V-PCO. AMH ,10.7 ng/mL discriminated V-PCO from PCOS with 96% specificity and 41% sensitivity for PCOS-T, and insignificantly for PCOS-A.. Conclusion(s): ...
Side Effects for MAKENA (hydroxyprogesterone caproate injection) are also known as adverse reactions. Below is a summary of known side effects for Makena.
A synthetic progestin that is derived from 17-Hydroxyprogesterone. It is a long-acting contraceptive that is effective both orally or by Intramuscular Injection and has also been used to treat Breast and Endometrial Neoplasms ...
Pereira, O.M.; Cruz Ortiz, S.G.; Llorens, A.; Rosa, E.Rivera., 2014: Pregnancy and neonatal outcomes of women receiving compounded 17-alpha hydroxyprogesterone at San Juan City hospital
11β-hydroxylase deficiency (11β-OHD), an autosomal recessive inherited disorder, accounts for 5-8% of congenital adrenal hyperplasia. In Greece, no cases of 11β-OHD have been described so far. The patient presented at the age of 13 months with mild virilization of external genitalia and pubic hair development since the age of 3 months. Hormonal profile showed elevated 11-deoxycortisol, adrenal androgens and ACTH levels. ACTH stimulation test was compatible with 11β-OHD. DNA of the proband and her parents was isolated and genotyped for CYP11B1 gene coding cytochrome P450c11. The girl was found to be compound heterozygous for two CYP11B1 novel mutations, p.Ala386Glu (exon 7), inherited from the father and p.Leu471Argin (exon 9) from the mother. Hydrocortisone supplementation therapy was initiated. Four years after presentation she remains normotensive, her growth pattern is normal and the bone age remains advanced despite adequate suppression of adrenal androgens. ...
My daughter was born with Salt-wasting congenital adrenal hyperplasia, she has developed a Gi bleed at 2 weeks old, corrective surgery at age of 9months, diagnosed with Hypothyroidism at age of 3. Onc...
Dr. Speiser has had a long-standing interest in congenital adrenal hyperplasia (CAH) and related disorders. She served as Chair of The Endocrine Society Task Force for Clinical Practice Guidelines for CAH and is on the Medical Advisory Boards of The CARES Foundation and the National Adrenal Diseases Foundation. Other clinical research interests include childhood growth, obesity and diabetes. Dr. Speiser has received foundation funding to study the natural history of diabetes risk factors in middle school children as part of a consortium of several metropolitan New York are hospitals, and has participated in TRIALNET, a multicenter diabetes trial sponsored by The National Institutes of Health.. Dr. Speiser is currently involved in an NIH-sponsored multicenter clinical trial to test the safety and efficacy of a novel drug for congenital adrenal hyperplasia in children. Our team is also participating in a study sponsored by Rhythm Pharmaceuticals to identify youngsters with genetic traits ...
Adrenal cortex synthesize steroids. Mnemonic: GFR - Salt, Sugar, Sex Zona gomerulosa: Salt (Aldosterone) Zona fasciculata: Sugar (Cortisol) Zona reticulosa:
Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 3.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/3.0/ ...
We have had several members whose dogs have been diagnosed as having congenital adrenal hyperplasia-like syndrome, and we have many other people asking about Atypical Cushings, so this is for anyone who might be looking for information on those conditions. If a dog continues to exhibit Cushings symptoms, yet tests negative or borderline for Cushings on the usual tests (ACTH stimulation test and Low Dose dexamethasone suppression test) your Vet or Internal Medicine Specialist Vet may
We have had several members whose dogs have been diagnosed as having congenital adrenal hyperplasia-like syndrome, and we have many other people asking about Atypical Cushings, so this is for anyone who might be looking for information on those conditions. If a dog continues to exhibit Cushings symptoms, yet tests negative or borderline for Cushings on the usual tests (ACTH stimulation test and Low Dose dexamethasone suppression test) your Vet or Internal Medicine Specialist Vet may
I have a 12 year old daughter who was born with a condition called congenital adrenal hyperplasia(CAH). I have recently learned from doing computer research on this condition that it could have been detected before she was born. I had an amniocintesis done when I was 5.5 months pregnant with her,I was told she was going to be born with open spinabifada, I knew that was wrong because she moved to much during pregnancy so I was given a wrong diagnosis. I have also learned that there are some things with her CAH that could have been prevented with correct diagnosis and proper treatment during pregnancy. How could such a mistake have been made.. Reply Follow This Thread Stop Following This Thread Flag this Discussion ...
CAH. CAH is an inherited disorder in which the adrenal glands produce low levels of cortisol and aldosterone and increased levels of androgens. Elevated 17-hydroxyprogesterone is seen in CAH, a result of 21-hydroxylase deficiency, and elevated DHEAS further indicates an adrenal source. Cortisol secretion is decreased in CAH ...
Question - Oxyelite pro and CAH. Ask a Doctor about diagnosis, treatment and medication for Congenital adrenal hyperplasia, Ask an Internal Medicine Specialist
Dexamethasone has also been used during pregnancy as an off-label prenatal treatment for the symptoms of congenital adrenal hyperplasia (CAH) in female fetuses. CAH causes a variety of physical abnormalities, notably ambiguous genitalia in girls.
My younger daughter was prescribed with Florinef three months ago, may be this period of time is not sufficient to judge about the efficiency of a corticosteroid but I am so pleased with the way Florinef works that I decided to share my opinion with others. Our diagnosis is congenital adrenal hyperplasia, as our doctor - pediatric endocrinologist - explained it means that my daughters adrenal glands dont produce enough cortisol for her body. She was diagnosed at an early age, when her height and weight just slightly differed from the norm. The doctor prescribed Florinef to boost the levels of deficient hormones in my baby. Since the time we started on Florinef we undergo regular tests to monitor her condition and according to the test results the medication works perfectly well. There is almost no threat for her normal growth. The prognosis is very optimistic. With the help of Florinef my daughter will be able to grow normally, the only condition is careful dosage of the medication and regular ...
A UK study published in Clinical Endocrinology assesses rates of obesity and high blood pressure in children with congenital adrenal hyperplasia attending a single clinic. Full article...
The thing is, the results of these tests will only go so far. They cant tell you if your levels are high or adrenal-hyperplasia-high. The endo called this a "grey zone," where adrenal hyperplasia still cant be confirmed or ruled out, and further testing is required. And so I am waiting for a nurse from the lab at the hospital to schedule me ACTH stimulation test. I am not going to look this up right now, I think Id rather not know too much about it and risk making myself more nervous, but the endo did explain in a nutshell what happens. I go in, the nurse injects me with something that will stimulate the production of hormones, then do a blood test 30 and 60 minutes afterward. I think Ill be able to handle that, but still, it being at the hospital and something Ive never done before, I know Ill get more and more anxious closer to. So Id appreciate it if readers didnt share their horror stories about this test or anything. Ignorance is bliss right now ...
The enzyme 20α-hydroxysteroid dehydrogenase (20α-HSD) catalyzes the conversion of progesterone to its inactive form, 20α-hydroxyprogesterone. This enzyme has been shown to play a critical role in the regulation of luteal function in experimental animals. In this study, we cloned and expressed the gene encoding elk deer 20α-HSD from reproductive placental ...
Classic congenital adrenal hyperplasia affects approximately 1 in 15,000 children. Current treatment strategies using multiple daily doses of hydrocortisone lead to suboptimal outcomes. We tested the hypothesis that nocturnal administration of dexamethasone will suppress the hypothalamic-pituitary-adrenal axis more effectively than standard hydrocortisone treatment by blocking the inherent diurnal secretion of ACTH. We performed a pilot study of five prepubertal patients comparing CAH control during two 24-hour hospitalizations, one on hydrocortisone and the other on dexamethasone. The patterns of adrenal suppression differed markedly between hydrocortisone and nocturnal dexamethasone, with significant suppression of the morning rise in ACTH, 17-hydroxyprogesterone, and androstenedione while on dexamethasone. On hydrocortisone therapy, there is a marked variation in ACTH and adrenal hormones depending on time of day and timing of hydrocortisone administration. Longer-term studies are needed to
TY - JOUR. T1 - Impact of Pregnancy History and 17-Hydroxyprogesterone Caproate on Cervical Cytokines and Matrix Metalloproteinases. AU - Caritis, Steve N.. AU - Hankins, Gary. AU - Hebert, Mary. AU - Haas, David M.. AU - Ahmed, Mahmoud. AU - Simhan, Hyagriv. AU - Haneline, Laura A.. AU - Harris, John. AU - Chang, Justine. AU - Famy, Alyssa Stephenson. AU - Yorio, Patrick. AU - Ren, Zhaoxia. AU - Dalton, Mary E.. AU - Venkataramanan, Raman. PY - 2017/11/15. Y1 - 2017/11/15. N2 - Objective The objective of this study was to evaluate the impact of pregnancy history and 17-hydroxyprogesterone caproate (17-OHPC) treatment on cervical fluid cytokines and matrix metalloproteinases (MMPs). Study Design Cervical fluid was obtained between 16 0/7 and 24 6/7 weeks from women with only prior term births (controls, n = 26), women with one or more prior spontaneous preterm births (SPTBs) choosing to receive 17-OHPC (17-OHPC, n = 24), or to not receive 17-OHPC (refusers, n = 12). Cervical fluid collections ...
there may be clinical and laboratory finding. The aim was to evaluate the epidemiology and clinical finding of CAH. The clinical and laboratory characteristics of 68 patients with CAH who were managed in the pediatric Endocrinology unit of Imam Reza Hospital during 7 years were recorded in this study; the clinical and epidemiological characteristics of congenital adrenal hyperplasia were evaluated in 68 patients admitted Imam Reza Hospital in Mashed, also one patient has been followed in endocrine and metabolism pediatric clinic in this time, during 6 years retrospectively and I year prospectively. Parental consanguinity rate among families of patients was higher than the general population in Mashad [73.8% vs 30%]. In 44.6% of patients the history of disease were positive in sibling.52.2% of patients were males and 47.8% females.21- Hydroxylase deficiency was present in 60 patients [88.2%], salt - losing form in 40 [66.7%] and simple virilizing form in 20 [33.3%] of them.11- beta hydroxylase ...
Congenital hyperplasia of the adrenal glands is a rare pathology, which can have an impact on male fertility. We report 2 cases of azoospermia in patients followed for a classical form of congenital adrenal hyperplasia. 1st case: After 18 months of infertility of the couple, explorations showed a high level of ACTH on the hormonal biological analysis. A therapeutic strategy combining hydrocortisone with dexamethasone induced a normal semen analysis, and the female partner of the patient subsequently had three spontaneous pregnancies. 2nd case: After two years of infertility of the couple, explorations showed adrenal testicular inclusions invading the 4/5th of the testis with a hypergonadotropic hypogonadism, the therapeutic reinforcement did not allow the improvement of semen analysis. Sertolian deficiency can be explained by: gonadotropic deficiency by excess of adrenal androgens and adrenal testicular lesions (risk of major spermatic alteration). Congenital hyperplasia of the adrenal glands is a rare
Congenital adrenal hyperplasia (CAH) is an inherited autosomal recessive disorder characterized by insufficient production of cortisol. The aim of this case report was to present a child with CAH, premature exfoliation of primary teeth and accelerated eruption of his permanent teeth related to bone resorption. A 4.5-year-old Caucasian boy with CAH and long-term administration of glucocorticoids was referred for dental restoration. Clinical examination revealed primary molars with worn stainless steel crowns, severe attrition of the upper canines, and absence of the upper incisors. Before the completion of treatment, abnormal mobility of the first upper primary molars and the lower incisors was detected, and a few days later the teeth exfoliated prematurely. Histologic examination revealed normal tooth structure. Alkaline phosphatase and blood cells values were normal. Eruption of the permanent dentition was also accelerated. Tooth mobility was noticed in the permanent teeth as soon as they erupted,
In infants with failure to thrive, salt wasting and (most obviously in baby girls with clitoromegaly, fused labia, and a persistent urogenital sinus) congenital adrenal hyperplasia must be ruled out. The same is true in boys who present with pseudoprecocious puberty and in older girls with signs and symptoms of hyperandrogenism, although, in teenage girls, polycystic ovary is the most common cause.. Congenital adrenal hyperplasia can be reliably diagnosed with a dexamethasone suppression test. Apart from a few rare causes of hyperandrogenism including exaggerated adrenarche secondary to adrenal hyperresponsiveness to ACTH, hyperprolactinemia, and acromegaly, congenital adrenal hyperplasia is the only virilizing condition in which androgen secretion is suppressed by dexamethasone. ACTH levels can be used to confirm the diagnosis if it is still questionable. An increase in plasma 17-OHP to more than 1200 ng/dL at 60 minutes in response to an IV injection of 250 mcg of cosyntropin is diagnostic of ...
Compliance Statement B: For laboratory developed tests not using a RUO kit, and for FDA approved, cleared or 510(k) exempt assays with alterations. This test was developed and its performance characteristics determined by ARUP Laboratories. The U. S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions ...
Note that 3,17-diacetoxy-6-methylpregna-4,6-dien-20-one (1b), a structural analog of compound 1a, is certified in Russia under ... Acetomepregenol (brand name Diamol), or mepregenol diacetate, also known as 3β,17α-diacetoxy-6-methylpregna-4,6-dien-20-one, is ... Nikitina GV, Savchenko ON, Stepanov MG (1987). "[Hormonal properties of new 17 alpha-hydroxyprogesterone derivatives]". ... "Investigation of the Gestagen Activity of 17α-acetoxy-3β-butanoyloxy-6-methylpregna-4,6-dien-20-one". Pharmaceutical Chemistry ...
Progesterone → (hydroxylation at C17) → 17-alpha-hydroxyprogesterone → (hydroxylation at C21) → 11-Deoxycortisol → ( ...
Whereas hydroxyprogesterone acetate (the 6α-demethylated analogue of medroxyprogesterone acetate) is around twice as potent as ... 3-hydroxyprogesterone. * Prodox, Upjohn Co., Kalamazoo, Michigan [...] It was found that 17-a-hydroxyprogesterone acetate has a ... doi:10.1210/jcem-17-10-1237. PMID 13475464. It is the purpose of this paper to introduce and describe a new steroid for oral ... Dimethisterone, also known as 6α,21-dimethylethisterone or as 6α,21-dimethyl-17α-ethynyltestosterone, as well as 17α-ethynyl-6α ...
... such as hydroxyprogesterone caproate, medroxyprogesterone acetate, and cyproterone acetate, are highly active themselves (and ... and hydroxyprogesterone caproate, the 19-norprogesterone derivative nomegestrol acetate, and the 19-nortestosterone derivatives ... hydroxyprogesterone, medroxyprogesterone, and cyproterone, respectively). On the other hand, esters of 19-nortestosterone ... One promising ester, [17α-hydroxyprogesterone acetate], marketed as Prodox, was found. It was more active by mouth than other ...
"16α-hydroxyprogesterone: origin, biosynthesis and receptor interaction". Mol. Cell. Endocrinol. 336 (1-2): 92-101. doi:10.1016/ ... Other endogenous progestogens include 16α-hydroxyprogesterone, 17α-hydroxyprogesterone, 20α-dihydroprogesterone, 5α- ... These progestogens, along with another steroid, 17α-hydroxypregnenolone, are the precursors of all other endogenous steroids, ... Major examples of progestins include the 17α-hydroxyprogesterone derivative medroxyprogesterone acetate and the 19- ...
21-hydroxyprogesterone), respectively, and pregnanetriols are formed secondarily to 17α-hydroxylation. In addition, ... 17 (5): 367-88. doi:10.1089/neu.2000.17.367. PMID 10833057. Pan DS, Liu WG, Yang XF, Cao F (October 2007). "Inhibitory effect ... Finally, the diketone 17 undergoes an intramolecular aldol condensation by treating with aqueous potassium hydroxide to produce ... 93 (17): 4332-4. doi:10.1021/ja00746a062. PMID 5131151. Coutinho EM, Segal SJ (1999). Is Menstruation Obsolete?. Oxford ...
In addition to progesterone, 20α- and 20β-hydroxyprogesterone (20α- and 20β-hydroxy-4-pregnene-3-one) also are found. These ... Storbeck KH, Swart P, Africander D, Conradie R, Louw R, Swart AC (2011). "16α-hydroxyprogesterone: origin, biosynthesis and ... include 16α-hydroxyprogesterone (16α-OHP),[8] 17α-hydroxyprogesterone (17α-OHP) (very weak),[9] 20α-dihydroprogesterone (20α- ... These progestogens, along with another steroid, 17α-hydroxypregnenolone, are the precursors of all other endogenous steroids, ...
In contrast, ethisterone and other progestogens such as progesterone and hydroxyprogesterone caproate were not associated with ... anhydro-hydroxy-progesterone; and pregneninolone. Inhoffen, H. H.; Hohlweg, W. (1938). "Neue per os-wirksame weibliche ... This substance has been referred to in the literature as Δ4 pregnen-in-20-on-3-ol-17; Δ4 pregnene-in, 17-ol, 3-one; ethinyl ... Robert J. Kurman (17 April 2013). Blaustein's Pathology of the Female Genital Tract. Springer Science & Business Media. pp. 390 ...
17-alpha-hydroxyprogesterone → (hydroxylation at C21) → 11-Deoxycortisol → (hydroxylation at C11) → Cortisol The adrenal cortex ...
17alpha-hydroxyprogesterone + NAD(P)H + H+ The 3 substrates of this enzyme are 17alpha,20alpha-dihydroxypregn-4-en-3-one, NAD+ ... Wiest WG (December 1968). "On the function of 20 alpha-hydroxypregn-4-en-3-one during parturition in the rat". Endocrinology. ... In enzymology, a 20-α-hydroxysteroid dehydrogenase (EC 1.1.1.149) is an enzyme that catalyzes the chemical reaction 17alpha, ... 3β(or 20α)-hydroxysteroid dehydrogenase AKR1C1 Shikita M, Inano H, Tamaoki B (1967). "Further studies on 20-alpha- ...
"6-methyl-17alpha-hydroxyprogesterone, the lower fatty acid 17-acylates and methods for producing the same", published 1968-04- ... Penning TM, Sharp RB, Krieger NR (December 1985). "Purification and properties of 3 alpha-hydroxysteroid dehydrogenase from rat ... selective inhibition of 3 alpha-hydroxysteroid oxidoreductase activity". Journal of Steroid Biochemistry. 17 (2): 197-203. doi: ... On November 17, 2004, the United States Food and Drug Administration put a black box warning on the label, indicating that ...
File "2006 MeSH Trees".) MeSH D04.345.051.500 --- crown ethers MeSH D04.345.103.222 --- alpha-cyclodextrins MeSH D04.345. ... 5-alpha-dihydroprogesterone MeSH D04.808.745.558.050 --- alfaxalone alfadolone mixture MeSH D04.808.745.558.783 --- ... 20-alpha-dihydroprogesterone MeSH D04.808.745.745.654.829.395 --- hydroxyprogesterones MeSH D04.808.745.745.654.829.395.400 ... 17-diol MeSH D04.808.054.040.129 --- androsterone MeSH D04.808.054.040.248 --- dihydrotestosterone MeSH D04.808.054.040.248.450 ...
The first product was 17alpha-acetoxyprogesterone4 (Figure 1) marketed under the trade name of Prodox.® Prodox was introduced ... 17a-hydroxyprogesterone caproate and 17a-hydroxyprogesterone acetate, introduced in 1953, and the most potent of all new ... Hydroxyprogesterone acetate is the generic name of the drug and its INN. OHPA is or was marketed under the brand name Prodox ... of hydroxyprogesterone a c e t a te, in bottles of 25 tablets. GREENBLATT RB (1959). "Hormonal control of functional uterine ...
... is the generic name of OHPC and its INN, USAN, BANM, and JAN, while hydroxyprogesterone hexanoate ... 17a-hydroxyprogesterone caproate and 17a-hydroxyprogesterone acetate, introduced in 1953, and the most potent of all new ... hydroxyprogesterone acetate, hydroxyprogesterone heptanoate, medroxyprogesterone acetate, and megestrol acetate. Along with ... Hydroxyprogesterone caproate (OHPC), sold under the brand names Proluton, Proluton Depot, and Makena among others, is a ...
In enzymology, a 17α-hydroxyprogesterone aldolase (EC 4.1.2.30) is an enzyme that catalyzes the chemical reaction 17α- ... hydroxyprogesterone ⇌ {\displaystyle \rightleftharpoons } androst-4-en-3,17-dione + acetaldehyde Hence, this enzyme has one ... The systematic name of this enzyme class is 17α-hydroxyprogesterone acetaldehyde-lyase (4-androstene-3,17-dione-forming). Other ... 17α-hydroxyprogesterone, and two products, androst-4-en-3,17-dione and acetaldehyde. This enzyme belongs to the family of ...
... including hydroxyprogesterone caproate, as well as hydroxyprogesterone acetate and hydroxyprogesterone heptanoate to a much ... Hydroxyprogesterone is the generic name of 17α-OHP and its INN and BAN. 11α-Hydroxyprogesterone 5α-Dihydroprogesterone 20- ... Among others, this class of drugs includes chlormadinone acetate, cyproterone acetate, hydroxyprogesterone caproate, ... hydroxyprogesterone caproate. 17α-OHP, also known as 17α-hydroxypregn-4-ene-3,20-dione, is a naturally occurring pregnane ...
... alpha subunit MeSH D06.472.351.576.463 --- luteinizing hormone MeSH D06.472.351.576.463.249 --- glycoprotein hormones, alpha ... 20-alpha-dihydroprogesterone MeSH D06.472.334.851.687.750.099 --- 5-alpha-dihydroprogesterone MeSH D06.472.334.851.687.750.478 ... alpha-msh MeSH D06.472.699.631.525.690.583.075 --- beta-msh MeSH D06.472.699.631.525.690.583.115 --- gamma-msh MeSH D06.472. ... alpha-msh MeSH D06.472.734.525.690.583.075 --- beta-msh MeSH D06.472.734.525.690.583.115 --- gamma-msh MeSH D06.472.734.525.883 ...
Glass TL, Lamppa RS (1985). "Purification and properties of 16 alpha-hydroxyprogesterone dehydroxylase from Eubacterium sp. ... 16alpha-hydroxyprogesterone dehydroxylase, 16alpha-dehydroxylase, and 16alpha-hydroxyprogesterone hydro-lyase. ... In enzymology, a 16alpha-hydroxyprogesterone dehydratase (EC 4.2.1.98) is an enzyme that catalyzes the chemical reaction ... The systematic name of this enzyme class is 16alpha-hydroxyprogesterone hydro-lyase (16,17-didehydroprogesterone-forming). ...
11 alpha-Hydroxyprogesterone (11 alpha OH-P) was an order of magnitude more potent a competitive inhibitor of the 11 beta HSD-2 ... Souness GW, Latif SA, Laurenzo JL, Morris DJ (1995). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta- ... Souness GW, Morris DJ (1996). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid ... 11α-Hydroxyprogesterone can therefore influence blood pressure regulation.12 Furthermore, 11α-hydroxyprogesterone exhibits an ...
Souness GW, Latif SA, Laurenzo JL, Morris DJ (1995). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta- ... Souness GW, Morris DJ (1996). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid ... 11β-Hydroxyprogesterone (11β-OHP), also known as 21-deoxycorticosterone, as well as 11β-hydroxypregn-4-ene-3,20-dione, is a ... Along with its epimer 11α-hydroxyprogesterone (11α-OHP), 11β-OHP has been identified as a very potent competitive inhibitor of ...
It is an alpha-globulin. This gene encodes an alpha-globulin protein with corticosteroid-binding properties. This is the major ... "Entrez Gene: SERPINA6 serpin peptidase inhibitor, clade A (alpha-1 antiproteinase, antitrypsin), member 6". E. Edward Bittar; ... allelic association and a unique haplotype associated with alpha 1-antitrypsin deficiency". Am J Hum Genet. 55 (1): 126-33. PMC ... Aldosterone - Approximately 17% of serum aldosterone is bound to transcortin, while another 47% is bound to serum albumin. The ...
Hydroxyprogesterone acetate. *Hydroxyprogesterone caproate (hydroxyprogesterone hexanoate). *Hydroxyprogesterone heptanoate ( ... Redirected from 5-alpha-dihydroprogesterone). Jump to: navigation, search 5α-Dihydroprogesterone. ... 5S,8R,9S,10S,13S,14S,17S)-17-acetyl-10,13-dimethyl-1,2,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3- ... InChI=1S/C21H32O2/c1-13(22)17-6-7-18-16-5-4-14-12-15(23)8-10-20(14,2)19(16)9-11-21(17,18)3/h14,16-19H,4-12H2,1-3H3/t14-,16-,17+ ...
In animals, it is approximately 25 times more potent than progesterone or hydroxyprogesterone caproate. In humans, 100 or 200 ... or 17alpha-hydroxy-19-nor-progesterone-caproate (DepostatB, Schering), 200 mg daily. These doses can be considered as ... The preparations used were Proluton Depot (17a-hydroxy-progesterone caproate) and in 3 patients SH 5132 (17a-hydroxy-19- ... Like the closely related progestins hydroxyprogesterone caproate and 19-norprogesterone, gestonorone caproate shows poor ...
Souness GW, Latif SA, Laurenzo JL, Morris DJ (1995). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta- ... Souness GW, Morris DJ (1996). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid ... alpha)-methyl-androsta-1,4-diene-11 (alpha), 17 (beta)-diol-3-one) in humans". J. Int. Med. Res. 4 (2): 96-105. doi:10.1177/ ... Indeed, 11α- and 11β-hydroxyprogesterone (formebolone and roxibolone being 11α- and 11β-hydroxylated (respectively) similarly) ...
Souness GW, Latif SA, Laurenzo JL, Morris DJ (1995). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta- ... Souness GW, Morris DJ (1996). "11 alpha- and 11 beta-hydroxyprogesterone, potent inhibitors of 11 beta-hydroxysteroid ... In accordance, 11α- and 11β-hydroxyprogesterone are known to be potent inhibitors of 11β-hydroxysteroid dehydrogenase (11β-HSD ... Roxibolone (INN) (developmental code name BR-906), also known as 11β,17β-dihydroxy-17α-methyl-3-oxoandrosta-1,4-diene-2- ...
InChI=1S/C15H11I4NO4/c16-8-4-7(5-9(17)13(8)21)24-14-10(18)1-6(2-11(14)19)3-12(20)15(22)23/h1-2,4-5,12,21H, 3,20H2, (H, 22,23)/ ... 17] Levothyroxine is taken on an empty stomach approximately half an hour to an hour before meals.[18] As such, thyroid ...
CHEBI:17252 - 17α-hydroxyprogesterone. Main. ChEBI Ontology. Automatic Xrefs. Reactions. Pathways. Models. ... 17α-hydroxyprogesterone (CHEBI:17252) is a 17α-hydroxy-C21-steroid (CHEBI:138141) 17α-hydroxyprogesterone (CHEBI:17252) is a ... 17α-hydroxyprogesterone (CHEBI:17252) has role progestin (CHEBI:59826) 17α-hydroxyprogesterone (CHEBI:17252) is a 17α-hydroxy ... 17(16). 7-. 10-. 20(18,21). 3/h12,16-. 18,24H,4-. 11H2,1-. 3H3/t16-. ,17+,18+,19+,20+,21+/m1/s1. ...
In enzymology, a 17α-hydroxyprogesterone aldolase (EC 4.1.2.30) is an enzyme that catalyzes the chemical reaction 17α- ... hydroxyprogesterone ⇌ {\displaystyle \rightleftharpoons } androst-4-en-3,17-dione + acetaldehyde Hence, this enzyme has one ... The systematic name of this enzyme class is 17α-hydroxyprogesterone acetaldehyde-lyase (4-androstene-3,17-dione-forming). Other ... 17α-hydroxyprogesterone, and two products, androst-4-en-3,17-dione and acetaldehyde. This enzyme belongs to the family of ...
17α-Hydroxyprogesterone Coated Tube RIA Kit The kit is ready to use and includes the following components: Antibody Coated ... 17α-Hydroxyprogesterone Double Antibody RIA Kit The kit is ready to use and includes the following components: Antiserum, 7 ... 17α-Hydroxyprogesterone Antiserum for 3H Assay (Sheep) Antibody is purified from sheep and is sufficient for 1,000 tubes. ...
... alpha-Hydroxyprogesterone Caproate. Robert Egerman,1 Risa Ramsey,2 Niki Istwan,3 Debbie Rhea,3 and Gary Stanziano3 ... alpha-hydroxyprogesterone caproate (17OHPC) for preterm delivery prevention. Materials and Methods. Retrospectively identified ... alpha-hydroxyprogesterone caproate (17OHPC) administration to women with a singleton gestation having a history of a preterm ... α-hydroxyprogesterone caproate," The New England Journal of Medicine, vol. 348, no. 24, pp. 2379-2385, 2003. View at Google ...
This study was undertaken to assess the impact of 17 alpha hydroxyprogesterone caproate treatment on future medical costs for ... Data on the costs of preterm birth were combined with published data on the effectiveness of 17 alpha hydroxyprogesterone ... These estimates were compared with an estimate of the cost of a typical 17 alpha hydroxyprogesterone caproate treatment regimen ... Treatment is estimated to reduce initial neonatal hospitalization costs by $3800 per woman treated with 17 alpha ...
6 alpha Methyl 17alpha hydroxyprogesterone Acetate. A synthetic progestin that is derived from 17-Hydroxyprogesterone. It is a ...
11-hydroxyprogesterone. Castor Oil. Progestins. Hormones. Hormones, Hormone Substitutes, and Hormone Antagonists. Physiological ... Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate. The safety and scientific validity ... The objective of our study is to compare the effectiveness of weekly intramuscular injections of 17-alpha Hydroxyprogesterone ... Prevention of Preterm Delivery in Twin Pregnancies by 17 Alpha-hydroxyprogesterone Caproate. ...
Meaning of 17-alpha-hydroxyprogesterone. What does 17-alpha-hydroxyprogesterone mean? Information and translations of 17-alpha- ... hydroxyprogesterone in the most comprehensive dictionary definitions resource on the web. ... Definition of 17-alpha-hydroxyprogesterone in the Definitions.net dictionary. ... Discuss these 17-alpha-hydroxyprogesterone definitions with the community:. Word of the Day. Would you like us to send you a ...
Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 ... Impact of single nucleotide polymorphisms on P450 oxidoreductase and peroxisome proliferator-activated receptor alpha on ... Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 ... Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 ...
strong,Sheep anti Human 17-alpha-Hydroxyprogesterone-3-Cmo antibody,/strong, recognizes 17-Alpha-Hydroxyprogesterone-3-CMO, a ... Sheep anti Human 17-alpha-Hydroxyprogesterone-3-Cmo antibody recognizes 17-Alpha-Hydroxyprogesterone-3-CMO, a progestogen which ... Request a different product with the 17-alpha-Hydroxyprogesterone-3-Cmo specificity ...
... alpha»-Hydroxyprogesterone, TMS derivative. *Formula: C24H38O3Si ...
17-Alpha-Hydroxyprogesterone (17-OHP). View cart "Complete Blood Count" has been added to your cart. ... 17 OHP along with Cortisol and Androstenedione constitutes the best screening test for Congenital adrenal hyperplasia caused by ...
Synthesis of 19-nor-17 alpha-hydroxy-progesterone-caprona. By admin October 27, 2019 Uncategorized 0 Comments ... HomeSynthesis of 19-nor-17 alpha-hydroxy-progesterone-caprona. ...
Buy 17-α-Hydroxyprogesterone 17-acetate - CAS Number 302-23-8 from LGC Standards. Please login or register to view prices, ... Hydroxyprogesterone Acetate ;. Megestrol Acetate Imp. K (Pharmeuropa) ;Medroxyprogesterone Acetate Imp. H (EP) ; Megestrol ... InChI=1S/C23H32O4/c1-14(24)23(27-15(2)25)12-9-20-18-6-5-16-13-17(26)7-10-21(16,3)19(18)8-11-22(20,23)4/h13,18-20H,5-12H2,1-4H3/ ... K (EP) ; 3,20-Dioxopregn-4-en-17-yl Acetate ; Chlormadinone acetate EP impurity G ;. Read more.. ...
Active Comparator: hydroxyprogesterone caproate 250 mg Pregnant subject will receive 250mg of hydroxyprogesterone caproate ... Experimental: hydroxyprogesterone caproate 500 mg Pregnant subject will receive 500mg of hydroxyprogesterone caproate ... Hydroxyprogesterone Caproate. 11-hydroxyprogesterone. Premature Birth. Obstetric Labor, Premature. Obstetric Labor ... Relationship Between Plasma Concentration of Hydroxyprogesterone Caproate (17-OHPC) and Preterm Birth (PRO). The safety and ...
Human steroidogenic cytochrome P450 17A1 mutant A105L with substrate 17alpha-hydroxyprogesterone. *DOI: 10.2210/pdb4NKY/pdb ... Steroid 17-alpha-hydroxylase/17,20 lyase. A, B, C, D. 494. Homo sapiens. Mutation(s): 1 Gene Names: CYP17, CYP17A1, S17AH. EC: ... 9beta)-17-hydroxypregn-4-ene-3,20-dione. C21 H30 O3. DBPWSSGDRRHUNT-CEGNMAFCSA-N. Ligand Interaction. ... Although 17α-hydroxyprogesterone is only observed farther from the catalytic iron, 17α-hydroxypregnenolone is also observed ...
... alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, ... alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, glucose-6-phosphate dehydrogenase, hemoglobin A, ... 17. The sensor of claim 1. , wherein a thickness of the resistance domain is from about 0.05 microns to about 5 microns. ... Jun 17, 2003. Therasense, Inc.. Blood analyte monitoring through subcutaneous measurement. US6689265 *. Mar 23, 2001. Feb 10, ...
... rotating the sensor seventeen times by 120( for at least six layers of 360( coverage) and curing at 50(C under vacuum for 60 ... alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, ... alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, glucose-6-phosphate dehydrogenase, hemoglobin A, ... 17. The system of claim 1. , wherein the sensor is configured to extend from the housing by a distance, wherein the distance ...
... alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, ... alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, analyte-6-phosphate dehydrogenase, hemoglobinopathies ... Apr 17, 2012. Abbott Diabetes Care Inc.. Analyte monitoring and management device and method to analyze the frequency of user ... and are covered by a sensing membrane 17 and a biointerface membrane 18, which are attached by a clip 19. In alternative ...
Equipped with the best GMP factory of best quality 17 Alpha hydroxyprogesterone Factory for cosmetic, health care and human ... it is able to supply you with top quality 17 Alpha hydroxyprogesterone Factory USP/EP 99%, as well as the reactive intermediate ... Hydroxyprogesterone caproate. Synonyms: OHPC; Hydroxyprogesterone hexanoate; 17α-Hydroxyprogesterone caproate; 17α-OHPC; 17- ... Contact Now Hydroxyprogesterone Caproate,17α-Hydroxyprogesterone caproateProduct Name: ...
Pregnancy and neonatal outcomes of women receiving compounded 17-alpha hydroxyprogesterone at San Juan City hospital ... More than 75% of the patients prolonged their pregnancy with the use of 17alpha-hydroxyprogesterone. Continuation of the study ... To describe the pregnancy and neonatal outcomes of women receiving 17alpha-hydroxyprogesterone to prevent subsequent preterm ... Pregnancy and neonatal outcomes of women receiving compounded 17-alpha hydroxyprogesterone at San Juan City hospital. ...
The postnatal 17-OHP level may be considered as a measure for severity of intrauterine stress and might be used as an ... METHODS: We analyzed 17-OHP and TSH levels during neonatal screenings in the first hours of life of 90 premature infants born ... 17-alpha-Hydroxyprogesterone / blood*. Biological Markers / blood. Chorioamnionitis / blood*. Female. Fetal Growth Retardation ... 17-OHP was even higher when intrauterine growth restriction was present (99.8 nmol/L). Antenatal steroids and mode of delivery ...
Transforming Growth Factor Alpha (TGF-Alpha), Hepatocyte Growth Factor, Tumor Necrosis Factor-Alpha (TNF-Alpha), Placental ... Transforming Growth Factor Alpha, Hepatocyte Growth Factor, Tumor Necrosis Factor-Alpha, Angiogenin, Interleukin-8, Hypoxia ... Transforming Growth Factor Alpha, Hepatocyte Growth Factor, Tumor Necrosis Factor-Alpha, Angiogenin, Interleukin-8, Hypoxia ... alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, ...
... alpha-fetoprotein; amino acid profiles (arginine (Krebs cycle), histidine/urocanic acid, homocysteine, phenylalanine/tyrosine, ... alpha 1-antitrypsin, cystic fibrosis, Duchenne/Becker muscular dystrophy, analyte-6-phosphate dehydrogenase, hemoglobinopathies ... 17. The method of claim 15. , further comprising a step of filtering at least one glucose-related sensor data point when ... 17 alpha-hydroxyprogesterone; hypoxanthine phosphoribosyl transferase; immunoreactive trypsin; lactate; lead; lipoproteins ((a ...
Hydroxyprogesterone Caproate reference guide for safe and effective use from the American Society of Health-System Pharmacists ... The effect of esterases on 17alpha-hydroxyprogesterone caproate. Am J Obstet Gynecol. 2008; 198:229.e1-5. ... Identification of enzymes involved in the metabolism of 17alpha-hydroxyprogesterone caproate: an effective agent for prevention ... Hydroxyprogesterone Caproate Pharmacokinetics. Pharmacokinetics of the 250-mg dose of hydroxyprogesterone caproate not ...
  • Ethisterone is a synthetic androstane steroid which was derived from testosterone and is also known by the following synonyms: 17α-Ethynyltestosterone (or simply ethinyltestosterone or ethynyltestosterone) 17α-Ethynylandrost-4-en-17β-ol-3-one Pregn-4-en-20-yn-17β-ol-3-one (or simply pregneninolone or pregnenynolone) 20,21-Anhydro-17β-hydroxyprogesterone (or simply anhydrohydroxyprogesterone) Closely related analogues of ethisterone include vinyltestosterone, allyltestosterone, methyltestosterone, ethyltestosterone, and propyltestosterone. (wikipedia.org)
  • The report provides comprehensive information on the Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30, targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action MoA, route of administration RoA and molecule type. (bioportfolio.com)
  • Additionally, the report provides an overview of key players involved in Steroid 17 Alpha Hydroxylase/17,20 Lyase 17 Alpha Hydroxyprogesterone Aldolase or Cytochrome P450 17A1 or Cytochrome P450 C17 or Steroid 17 Alpha Monooxygenase or CYP17 or CYP17A1 or EC 1.14.14.19 or EC 4.1.2.30 targeted therapeutics development and features dormant and discontinued projects. (bioportfolio.com)
  • In contrast, the rare patient with 17α-hydroxylase deficiency will have very low or undetectable levels of 17OHP. (hmdb.ca)
  • 2. Lim YJ, Yong AB, Warne GL, Montalto J. Urinary 17 alpha-hydroxyprogesterone in management of 21-hydroxylase deficiency. (labcorp.com)
  • 3. Shibata Y. Determination of urinary 17 alpha-hydroxyprogesterone excretion using ELISA--evaluation of normal subjects and patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. (labcorp.com)
  • Mutations are associated with 17β-HSD type III deficiency. (wikipedia.org)
  • Mutations are associated with 17β-HSD type X deficiency (also known as HSD10 disease or MHBD deficiency) and mental retardation, X-linked, syndromic 10 (MRXS10), which are characterized by neurodegeneration and mental retardation, respectively. (wikipedia.org)
  • Mutations in this gene are associated with isolated steroid-17α-hydroxylase deficiency, 17α-hydroxylase/17,20-lyase deficiency, pseudohermaphroditism, and adrenal hyperplasia. (wikipedia.org)
  • Congenital adrenal hyperplasia due to 17α-hydroxylase deficiency is an uncommon form of congenital adrenal hyperplasia resulting from a defect in the gene CYP17A1, which encodes for the enzyme 17α-hydroxylase. (wikipedia.org)
  • This form of CAH results from deficiency of the enzyme 17α-hydroxylase (also called CYP17A1). (wikipedia.org)
  • Thus, medical textbooks and nosologies until quite recently described two different diseases: 17α-hydroxylase deficient CAH, and a distinct and even rarer defect of sex steroid synthesis termed 17,20-lyase deficiency (which is not a form of CAH). (wikipedia.org)
  • Some persons with 17α-hydroxylase deficiency develop hypertension in infancy, and nearly 90% do so by late childhood. (wikipedia.org)
  • These features of mineralocorticoid excess are the major clinical clue distinguishing the more complete 17α-hydroxylase deficiency from the 17,20-lyase deficiency, which only affects the sex steroids. (wikipedia.org)
  • Genetic XX females affected by total 17α-hydroxylase deficiency are born with normal female internal and external anatomy. (wikipedia.org)
  • Inactivating mutations resulting in a syndrome of congenital deficiency of 17β-HSD2 have not been reported to date. (wikipedia.org)
  • Estrogen insensitivity syndrome (EIS), or estrogen resistance, is a form of congenital estrogen deficiency or hypoestrogenism which is caused by a defective estrogen receptor (ER) - specifically, the estrogen receptor alpha (ERα) - that results in an inability of estrogen to mediate its biological effects in the body. (wikipedia.org)
  • Human placental 17 beta-estradiol dehydrogenase and 20 alpha-hydroxysteroid dehydrogenase. (wikipedia.org)
  • In 1995, 11α-OHP, along with its epimer 11β-hydroxyprogesterone, was identified as a very potent competitive inhibitor of both isoforms (1 and 2) of 11β-hydroxysteroid dehydrogenase (11β-HSD). (wikipedia.org)
  • 17β-Hydroxysteroid dehydrogenases (17β-HSD, HSD17B) (EC 1.1.1.51), also 17-ketosteroid reductases (17-KSR), are a group of alcohol oxidoreductases which catalyze the reduction of 17-ketosteroids and the dehydrogenation of 17β-hydroxysteroids in steroidogenesis and steroid metabolism. (wikipedia.org)
  • 17β-Hydroxysteroid dehydrogenase 2 (17β-HSD2) is an enzyme of the 17β-hydroxysteroid dehydrogenase (17β-HSD) family that in humans is encoded by the HSD17B2 gene. (wikipedia.org)
  • Third, substrate specificity of the subsequent 17,20-lyase reaction may be explained by variation in substrate height above the heme. (rcsb.org)